Street Talk

FDA knocks back QRxPharma

Sarah Thompson and Anthony Macdonald

Jun 28, 2012 – 1.53pm

Subscribe to gift this article

Gift 5 articles to anyone you choose each month when you subscribe.

Already a subscriber?

It was supposed to be QRxPharma ’s day in the sun – the day the powerful US Food and Drug Administration was to approve its pain-management drug MoxDuo.

But shares in the biotech more than halved after the FDA yesterday knocked it back, requesting additional information on safety and effectiveness of the drug.